Details for Patent: 8,684,969
✉ Email this page to a colleague
Which drugs does patent 8,684,969 protect, and when does it expire?
Patent 8,684,969 protects OZEMPIC and SAXENDA and is included in two NDAs.
Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventeen patent family members in fourteen countries.
Summary for Patent: 8,684,969
| Title: | Injection device with torsion spring and rotatable display |
| Abstract: | The present invention relates to an injection device comprising a torsion spring operatively connected to a dose setting member being adapted to set a dose to be ejected from the injection device. A rotatably mounted display member adapted to display the dose to be ejected in accordance with a setting of the dose setting member is also provided. The rotatably mounted display member is adapted to be rotated over an angle corresponding to at least one revolution of the display member. The display member may be implemented as a dose indicator barrel having numerals arranged along a helical path on an outer surface thereof, or alternatively, as a counting device having two or more display wheels having numerals arranged on an outer surface thereof. |
| Inventor(s): | Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsvaerd, DK), Enggaard; Christian Peter (Vejby, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 13/626,541 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,684,969 |
|
Patent Claim Types: see list of patent claims | Device; |
Drugs Protected by US Patent 8,684,969
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-004 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,684,969
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 04077899 | Oct 21, 2004 | |
International Family Members for US Patent 8,684,969
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E445430 | ⤷ Try a Trial | |||
| Australia | 2005298946 | ⤷ Try a Trial | |||
| Canada | 2584762 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
